Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARGX-117 long-term extension in adults with multifocal motor neuropathy
NL-OMON53633Phase 2Recruiting
- Sponsor
- argenx
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of empasiprubart in multifocal motor neuropathy (MMN), sponsored by argenx. Primary endpoint: Safety outcomes. Started Jan 2024; status: recruiting.
02
Drugs
empasiprubart
03
Conditions
multifocal motor neuropathy (MMN)
Beyond the preview
Go deeper on NL-OMON53633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53633.